[Decreased ethanol consumption by rats as affected by central alpha-adrenoblockaders: the role of liver aldehyde dehydrogenase isoenzymes].
It has been shown in the experiments on rats that subcutaneous administration of central alpha-adrenoblockers IEM-611 (30 mg/kg and 15 mg/kg) and phenoxybenzamine (10 mg/kg) for one or two weeks brings about a decrease in voluntary ethanol consumption at early stages of experimental alcoholism (3-week alcoholization). In rats with chronic alcoholization for 6 months only IEM-611 had a remarkable inhibitory effect on alcohol consumption. Moreover, it has been stated that IEM-611 reduced threefold the activity of liver aldehyde dehydrogenase (AlDH) by the inhibition of AlDH isoenzymes with low and high Km for acetaldehyde. Phenoxybenzamine inhibited slightly only low Km AlDH. It is suggested that differences in IEM-611 and phenoxybenzamine effects may be associated with specific drug inhibition of AlDH isoenzymes.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000428:Alcohol Drinking / Q000187:drug effects*; D000437:Alcoholism / Q000188:drug therapy / Q000201:enzymology; D000444:Aldehyde Dehydrogenase / Q000378:metabolism*; D000818:Animals; D044482:Benzeneacetamides; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D007527:Isoenzymes / Q000378:metabolism*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D010627:Phenethylamines / Q000494:pharmacology / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats
D000317:Adrenergic alpha-Antagonists; D044482:Benzeneacetamides; D007527:Isoenzymes; D010627:Phenethylamines; D010643:Phenoxybenzamine; C022075:IEM 611; D000444:Aldehyde Dehydrogenase
Snizhenie potrebleniia étanola krysami pod vliianiem tsentral'nykh al'fa-adrenoblokatorov: rol' izoferementov al'degiddegidrogenazy pecheni.